Carregando...
The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience
BACKGROUND: Rituximab, a monoclonal antibody directed against CD20, is approved for the treatment of CD20-positive B-cell Non-Hodgkin’s lymphoma and rheumatologic disorders. Due to its potent activity in depleting CD20-positive lymphocytes, the influence on opportunistic infections is still under di...
Na minha lista:
| Publicado no: | BMC Infect Dis |
|---|---|
| Principais autores: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4227097/ https://ncbi.nlm.nih.gov/pubmed/24992940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-14-364 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|